Expression of a photoreceptor protein, recoverin, as a cancer-associated retinopathy autoantigen in human lung cancer cell lines. by Matsubara, S. et al.
British Journal of Cancer (1996) 74, 1419-1422
© 1996 Stockton Press All rights reserved 0007-0920/96 $12.00 ov
Expression of a photoreceptor protein, recoverin, as a cancer-associated
retinopathy autoantigen in human lung cancer cell lines
S Matsubara, Y Yamaji, M Sato, J Fujita and J Takahara
First Department ofInternal Medicine, Kagawa Medical School, Ikenobe, Miki, Kagawa 761-07, Japan.
Summary Recently, a photoreceptor protein, recoverin, has been recognised as an autoantigen of cancer-
associated retinopathy (CAR), a rare paraneoplastic neurological syndrome often associated with patients with
small-cell lung cancer (SCLC). Although until quite recently the specific expression of recoverin in cancer cells
had not been indicated, Polans et al. (Polans AS, Witkowska D, Haley TL, Amundson D, Baizer L, Adamus G
1995, Proc. Natl. Acad. Sci. USA, 92, 9176-9180) demonstrated the specific expression of recoverin in lung
tumour and primary cultured tumour cells from a CAR patient. We examined the expression of recoverin in
human lung cancer cell lines by reverse transcription polymerase chain reaction (PCR), Northern blotting and
Western immunoblotting. Recoverin was expressed in only one SCLC cell line from a patient with CAR. The
sequence of recoverin cDNA from the cells was identical to the human recoverin sequence. These findings
strongly support the hypothesis that the ectopic expression ofwild-type recoverin in SCLC induces the cancer-
retina immunological cross-reaction, leading to visual loss in CAR.
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Cancer-associated retinopathy (CAR) is a rare paraneoplastic
neurological syndrome (PNS) but, when present, it is often
associated with small-cell lung cancer (SCLC) (Thirkill et al.,
1993). CAR is characterised by rapid and progressive visual
loss and retinal degeneration that occur in association with
cancer without direct invasion or metastasis of cancer to the
retina (Thirkill et al., 1989). While the mechanism for
paraneoplastic degenerative retinopathy has not been fully
elucidated, the presence of peculiar antibodies in patients who
suffer from this disease suggests that autoimmunity plays an
important pathogenic role in the development of CAR
(Thirkill et al., 1989, 1993). Recently, the CAR antigen was
identified as a 23 kDa photoreceptor protein, recoverin, from
the screening of retinal proteins in CAR patients' sera
(Polans et al., 1991; Thirkill et al., 1992). Recoverin is
specifically localised in the photoreceptor cells and partici-
pates in the recovery phase of visual excitation and in
adaptation to background light (Kawamura, 1994). While the
presence of shared epitopes between retina and cancer cells,
especially SCLC, had been proposed, such CAR antigen in
cancer cells had not been clarified (Thirkill et al., 1989, 1993)
until quite recently, when Polans et al. (1995) demonstrated
the specific expression of recoverin in the SCLC from a
patient associated with CAR. We have examined the
expression of recoverin in various human lung cancer cell
lines, including a cell line derived from an SCLC patient with
CAR.
Materials and methods
Cell lines
Ten SCLC cell lines and four non-SCLC cell lines were used
in this study. An SCLC cell line, designated MN-1112, was
established from a tumour of an SCLC patient with CAR
(Yamaji et al., 1996). The patient profile had been described
previously (Matsubara et al., 1996). Briefly, the patient was a
69-year-old man who had progressive bilateral visual loss.
Funduscopical examination, brain and ocular computerised
tomography and magnetic resonance imaging did not
demonstrate any abnormalities. Shortly after admission,
SCLC was found in the right lung. An autoantibody against
rat retina in the patient's serum was also demonstrated by
immunohistochemistry. Therefore, the patient was diagnosed
as having CAR associated with SCLC. Two SCLC cell lines,
H-69 and N-231, were obtained from Dr Futami (National
Cancer Center Research Institute, Tokyo, Japan) and an
SCLC cell line, LU-134-AM, and all non-SCLC cell lines
were provided by the Japanese Cancer Research Resources
Bank (JCRB). Other SCLC cell lines (KT-1027, TO-1019,
MT-428, MN-321 and M-319) were established from patients
without CAR at our laboratory (Fujita et al., 1994).
Reverse transcribed (RT) - PCR and direct sequencing analysis
A cDNA strand was synthesised from approximately 2 ,ug of
total RNA and subsequently amplified by polymerase chain
reaction (PCR), as previously described (Matsubara et al.,
1995). This primer pair was designed to amplify the recoverin
gene between exon 1 and exon 3 of the published human
recoverin sequence (Murakami et al., 1992). The primers used
for amplification from human recoverin sequence were 5'-
TGTGTTCCGCAGCTTCGATT-3'(sense) and 5'-TGA
GGCTCAAACTGGATCAG-3'(antisense). Thirty cycles
of PCR for human recoverin and 25 cycles of PCR for
human fl-actin were carried out using a thermal cycler (Sanko
Junyaku, Tokyo, Japan) according to the step programme of
94°C 80 s, 50°C 80 s, 72°C 80 s, followed by a 15 min
extension at 72°C. After amplification, the PCR product was
electrophoretically separated on a 1.5% agarose gel and
stained with ethidium bromide. Another amplified PCR
product (containing an entire coding region, 752 base pairs
in length) was sequenced by the direct dideoxy chain
termination method using a T7 sequencing kit (Pharmacia)
and [35S]dATP (>37 TBq mmol-, Amersham), as previously
described (Matsubara et al., 1995). The primers used for
amplification from the human recoverin sequence were 5'-
CAGCTCACACCAGCCTT-3' as the sense primer at an
upstream position from the start codon in exon 1 and 5'-
CACGGGTGTCATGTGAG-3' as the antisense primer at
a downstream position from the stop codon in exon 3. The
sequencing primers were chosen from those used to generate
the three nested PCR fragments.
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Northern blot analysis
Total RNAs from the lung cancer cell lines were extracted
as described above. Approximately 10 ,ug of each RNA
preparation was electrophoresed on a 0.4 M formaldehyde-
1% agarose gel, transferred to a Nytran membrane
(Schleicher and Shull, Keene, NH, USA) and hybridised
with a nick-translated 32P-labelled PCR clone of human
recoverin cDNA from MN- 1112 for 24 h at 42°C (Sato et
al., 1993). After autoradiography at room temperature for
24 h, hybridisation signals were detected using a Bioimaging
Analyser (BAS 1000 system, Fuji Photo Film, Tokyo,
Japan). The quantity and quality of RNA on the blot
were checked by hybridisation with human ,B-actin cDNA
probe.
Western immunoblot analysis
Confluent cultures of the ten SCLC cell lines were washed
with phosphate-buffered saline (PBS) and scraped, and cells
were collected and homogenised with a glass homogeniser in
lysis buffer [20 mM Tris-HCl, pH 7.4, 1 mM EGTA, 0.5 mM
DTT, 0.2 mm phenylmethylsulphonyl fluoride (PMSF)]. The
cells were sequentially centrifuged at 1 500 g for 15 min at
4°C. Each supernatant was collected. The protein content
was determined by a routine method (Fujita et al., 1994).
Each whole cell lysate of 30 ,ug, electrophoretically separated
on a 10-20% gradient gel, was transferred to a Clearblot P
membrane (Atto, Tokyo, Japan), which was then rinsed
three times with 50 mm Tris/400 mM sodium chloride (pH
7.5) buffer containing 0.05% Tween 20. The membrane was
incubated with 100 mm Tris/150 mM sodium chloride (pH
7.5) containing 2% blocking reagent (Boehringer Mannheim,
IN, USA) for 3 h at room temperature, then with a 1000-
fold diluted rabbit polyclonal anti-S-modulin antibody
(kindly obtained from Dr Kawamura, Osaka University,
Osaka, Japan) in the same buffer for 2 h. S-modulin is a
frog recoverin, of which the amino acid sequence shows an
83% identity to the bovine recoverin sequence. The
membrane was washed twice with the same solution for
30 min, and incubated for 1 h with a 10 000-fold diluted
alkaline phosphatase-conjugated goat anti-rabbit IgG
(Organon Teknika, Durham, NC, USA) in buffer contain-
ing 1% bovine serum albumin (BSA). After rinsing, blots
were developed using a chemiluminescence reaction (Lumi-
Phos 530, Boehringer Mannheim), then exposed to radio-
graphic film for 15 min. The hybridisation signals were
quantified on a scanning densitometer (CS-910, Shimadzu
Co., Kyoto, Japan).
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Results
Expression ofhuman recoverin gene in various human lung
cancer cell lines
The expression of recoverin mRNA in ten SCLC cell lines
(Figure la) and four non-SCLC cell lines (Figure lb) was
tested by RT-PCR. Recoverin mRNA was detected in only
one cell line, MN- 1112, which was derived from an SCLC of
a CAR patient. The additional PCR cycles (up to 40 cycles)
did not affect the result, exhibiting no recoverin mRNA
signal in the other lung cancer cell lines. The quality of
cDNA synthesised in these samples was assured by successful
amplification of a P-actin-specific gene, and the expression
level of the /3-actin gene was almost constant in all SCLC cell
lines tested.
We also sequenced the entire coding region of recoverin
cDNA from MN-1112. A comparison of this sequence with
the human retinal recoverin cDNA revealed a 100% identity
in the nucleic acid sequence, which contains a myristoilated
region at the N-terminus and three calcium binding sites, the
so-called EF-hands (data not shown).
The expression of human recoverin mRNA in human lung
cancer cell lines was analysed by Northern blotting (Figure
2). A transcript of approximately 1.4 kb was detected in MN-
1112. No transcript was detected in three other SCLC cell
lines. This transcript was quite similar in size to the published
human recoverin mRNA (Murakami et al., 1992).
Detection ofrecoverin immunoreactivities in the various human
SCLC cell lines by Western blots
The expression of recoverin immunoreactivities in various
SCLC cell lines was examined by Western immunoblotting
using a polyclonal rabbit anti-S-modulin antibody, which was
cross-reacted to the purified bovine recoverin (Figure 3). A
prominent single band was detected at a molecular weight
region of approximately 23 kDa in only the MN- 1112 whole
cell lysate. No recoverin-like immunoreactivity was found in
any other SCLC cell lines.
Discussion
The PNSs are frequently associated with SCLC, which
possesses many neuronal characteristics (Greco, et al.,
1981). The neuronal characteristics of SCLC are considered
to provide the antigenic stimulus required for production of a
cross-reacting immune response to the nervous system
targeted (Kornguth, 1989). The expression of some candi-
dates for PNS autoantigen, such as HuD protein for
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Figure 1 Expression of human recoverin and ,B-actin mRNAs in SCLC (a) and non-SCLC (b) cell lines detected by RT-PCR. PCR
products were run on a 1.5% agarose gel and visualised with ethidium bromide staining. HaeIII-digested 4X174DNA was used as a size
marker. The molecular size of PCR products was 369 and 504 base pairs (bp). The histological types were SCLC: MN- 112, H-69, N-231,
KT-1027, TO-1019, TK-130, MT-428, MN-321, M-319 and LU-134-AM; adenocarcinoma: PC-3 and A-549; squamous cell carcinoma; EBC-
1 and VMRC-LCD.
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paraneoplastic encephalomyelitis (Sekido et al., 1994) or
voltage-gated calcium channels for Lambert-Eaton myasthe-
nic syndrome (Ogura-Okano et al., 1992), has been examined
in various SCLC cell lines. However, these autoantigens were
expressed in almost all SCLC cell lines tested, both in the cell
lines related to PNS and in those not related to PNS. In these
cases, to explain rare events of PNS among the common
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Figure 2 Northern blot analysis of human recoverin mRNA in
SCLC cell lines. Northern blot filter containing lOug of total
RNA per lane was hybridised and separated on a 0.4M
formaldehyde- 1% agarose gel. (a) Hybridised with the 32p_
labelled human recoverin cDNA probe; arrow points to the
transcript of about 1.4kb. (b) The same blot hybridised with the
human ,B-actin probe. The size markers of 18S and 28S ribosomal
RNAs are indicated.
expression of such autoantigens in SCLC, some genetical
backgrounds in the cancer host have been proposed which
regulate the susceptibility to PNS. On the other hand, in
certain PNSs, such a paraneoplastic cerebellar degeneration,
the patient-specific expression of neural antigens was
demonstrated in tumour tissue from the patient (Furneaux
et al., 1990). In this study, we demonstrated that recoverin,
the retina-specific protein, is another such antigen for PNSs.
Using RT-PCR, we found the gene expression of recoverin,
as a conceivable candidate for the CAR autoantigen,
exclusively in only one SCLC cell line derived from a
patient with CAR (Figure 1). Its immunoreactivity was also
found in only this cell line by Western immunoblotting using
polyclonal anti-S-modulin antibody (Figure 3). Thirkill et al.
(1993) previously suggested that recoverin expression could
be induced in otherwise quiescent SCLC cell lines. However,
the expression of recoverin in an SCLC cell line, MN-1112,
was not induced during the establishment and passage of the
cell line because, as previously reported, the recoverin
expression was immunohistochemically demonstrated in a
primary SCLC tumour of the CAR patient from which the
cell line was derived (Matsubara et al., 1996).
Previous reports indicated that the presence of autoanti-
bodies to 23 kDa CAR antigen was highly specific for cancer,
especially for SCLC. Namely, there have been no reports
indicating a correlation between the antibody against 23 kDa
peptide and other forms of retinopathy including retinitis
pigmentosa, diabetic retinopathy and age-related macular
degenerations, in which a variety of antibodies are produced
against-retinal antigens (Thirkill et al., 1993). Furthermore, a
strong antigenicity of recoverin has already been proven by
the experiment that an injection of purified recoverin into
Lewis rats induced both cellular and humoral immune
activation, resulting in an experimental uveoretinitis
(Adamus et al., 1994; Gery et al., 1994). Both our and
these previous findings strongly suggest that the ectopic
expression of recoverin in SCLC cells could sensitise T cells
in the cancer host and also stimulate the production of
autoantibody from B cells, then induce the degeneration of
retina. However, whether a CAR patient possesses a
genetically determined susceptibility to induce such an
immune response remains unknown. It seems unlikely that
the presence of an autoantibody only reflects a non-specific
secondary response to retinal injury of other causes.
A spliced or point-mutated form of the responsible antigen
expressed in the tumours has been suggested to trigger an
autoimmune response in PNS (Dalmau et al., 1992). However,
our findings obtained from Northern blotting and sequencing
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Figure 3 Western blot analysis of recoverin in various SCLC cell lines. Whole cell lysates (30,ug) and purified bovine recoverin
(2pg) were separated on SDS/polyacrylamide (10-20% gradient gel) electrophoresis and transferred onto a Clearblot P membrane.
The membrane was incubated with a polyclonal rabbit anti-S modulin antibody, followed by goat anti-rabbit IgG coupled with
alkaline phosphatase (b). Proteins were visualised with Coomassie brilliant blue (a). Arrow indicates a band of recoverin. Molecular
masses of marker proteins (kilodaltons; kDa) are indicated on the left.
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ofrecoverin in the cells revealed no alternative splicing and no
point mutations in the entire coding region (Murakami et al.,
1992). This is in line with the above-mentioned animal model,
in which the uveoretinitis could be experimentally induced by a
purified wild-type form ofrecoverin.
In conclusion, our findings, together with the previous
reports, strongly support the hypothesis that autoimmunity
against the ectopic recoverin expressed in SCLC cells cross-
reacts with the corresponding antigen located in the retina
and induces retinal degeneration in a CAR patient.
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